openPR Logo
Press release

Biliary Atresia Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight | Albireo Pharma, Mirum Pharma

06-27-2024 04:24 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Biliary Atresia Market

Biliary Atresia Market

The Biliary Atresia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Atresia pipeline products will significantly revolutionize the Biliary Atresia market dynamics.

DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Biliary Atresia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Biliary Atresia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Atresia Market Insights
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Biliary Atresia Market Report:
• The Biliary Atresia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2023, Mirum Pharmaceuticals released top-line results from the Phase II EMBARK clinical study of Livmarli (maralixibat) oral solution in patients with biliary atresia. This double-blind, randomized, placebo-controlled trial assessed Livmarli's effectiveness and safety compared to a placebo in biliary atresia patients post Kasai surgery.
• As per the American Liver Foundation, up to 10-20% of infants with BA may have other associated malformations including multiple spleens, abnormal vessels supplying or draining the liver, or heart defects. About 75% of children with BA may eventually need a liver transplant
• According to the National Organization for Rare Disorders, BA occurs in approximately 1 in 10,000 to 15,000 births in the United States. Approximately 400-600 new cases of BA are encountered in the United States each year
• According to Burns J et.al., the prevalence of BA in Europe is approximately 1 in 12,000 births
• Key Biliary Atresia Companies: Albireo Pharma, Mirum Pharmaceuticals, Intercept Pharmaceuticals, and others
• Key Biliary Atresia Therapies: BYLVAY, LIVMARLI, OCA 0.1mg, Maralixibat, Odevixibat, and others
• The Biliary Atresia epidemiology based on gender analyzed that Biliary Atresia is slightly more common in female infants

Biliary Atresia Overview
According to National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) BA is a condition in infants in which the bile ducts-tubes inside and outside the liver-are scarred and blocked. Bile ducts carry bile from the liver to the gallbladder for storage, and to the first part of the small intestine, also called the duodenum, for use in digestion. In infants with BA, bile can't flow into the intestine, so bile builds up in the liver and damages it. The damage leads to scarring, loss of liver tissue and function, and cirrhosis.

Get a Free sample for the Biliary Atresia Market Report:
https://www.delveinsight.com/report-store/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Atresia Market
The dynamics of the Biliary Atresia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032.
"In October 2020, the United States Food and Drug Administration (USFDA) granted orphan drug status to Mirum Pharmaceuticals' LIVMARLI for the treatment of Biliary Atresia"

Biliary Atresia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Biliary Atresia Epidemiology Segmentation:
The Biliary Atresia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Biliary Atresia
• Prevalent Cases of Biliary Atresia by severity
• Gender-specific Prevalence of Biliary Atresia
• Diagnosed Cases of Episodic and Chronic Biliary Atresia

Download the report to understand which factors are driving Biliary Atresia epidemiology trends @ Biliary Atresia Epidemiological Insights
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Atresia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Atresia market or expected to get launched during the study period. The analysis covers Biliary Atresia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Atresia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Biliary Atresia Therapies and Key Companies
• BYLVAY: Albireo Pharma
• LIVMARLI: Mirum Pharmaceuticals
• OCA 0.1mg: Intercept Pharmaceuticals
• Maralixibat: Mirum Pharmaceuticals, Inc.
• Odevixibat: Albireo

To know more about Biliary Atresia treatment, visit @ Biliary Atresia Medications
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Atresia Market Drivers
• Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in Biliary Atresia
• The increasing prevalence of Biliary Atresia, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future.

Biliary Atresia Market Unmet Needs
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Biliary Atresia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Biliary Atresia Companies: Albireo Pharma, Mirum Pharmaceuticals, Intercept Pharmaceuticals, and others
• Key Biliary Atresia Therapies: BYLVAY, LIVMARLI, OCA 0.1mg, Maralixibat, Odevixibat, and others
• Biliary Atresia Therapeutic Assessment: Biliary Atresia current marketed and Biliary Atresia emerging therapies
• Biliary Atresia Market Dynamics: Biliary Atresia market drivers and Biliary Atresia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Atresia Unmet Needs, KOL's views, Analyst's views, Biliary Atresia Market Access and Reimbursement

Discover more about therapies set to grab major Biliary Atresia market share @ Biliary Atresia market forecast
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Biliary Atresia Market Report Introduction
2. Executive Summary for Biliary Atresia
3. SWOT analysis of Biliary Atresia
4. Biliary Atresia Patient Share (%) Overview at a Glance
5. Biliary Atresia Market Overview at a Glance
6. Biliary Atresia Disease Background and Overview
7. Biliary Atresia Epidemiology and Patient Population
8. Country-Specific Patient Population of Biliary Atresia
9. Biliary Atresia Current Treatment and Medical Practices
10. Biliary Atresia Unmet Needs
11. Biliary Atresia Emerging Therapies
12. Biliary Atresia Market Outlook
13. Country-Wise Biliary Atresia Market Analysis (2019-2032)
14. Biliary Atresia Market Access and Reimbursement of Therapies
15. Biliary Atresia Market Drivers
16. Biliary Atresia Market Barriers
17. Biliary Atresia Appendix
18. Biliary Atresia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia

Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biliary Atresia Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight | Albireo Pharma, Mirum Pharma here

News-ID: 3557094 • Views:

More Releases from DelveInsight Business Research

Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market. As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates. The Vitiligo Pipeline report offers extensive commercial and clinical
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Myelodysplastic Syndrome Pipeline Report • DelveInsight's Myelodysplastic Syndrome
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape. The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market. The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment

All 5 Releases


More Releases for Biliary

Global Metal Pancreatic Biliary Stent Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Metal Pancreatic Biliary Stent market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period. The metal pancreatic biliary stent market is witnessing consistent growth due to the rising prevalence of
Major Market Share Shift in Biliary Catheters Industry: Advancements In Biliary …
What Is the Forecasted Market Size and Growth Rate for the Biliary Catheters Market? The market size for biliary catheters has experienced robust growth in recent years. There is an expected growth from $3.42 billion in 2024 to $3.75 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 9.7%. Factors like increased occurrences of biliary tract ailments, the popularity of minimally invasive procedures, a growing aging population, more
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Biliary Stents Market - Unleashing Flow: Empowering Biliary Health with Innovati …
Newark, New Castle, USA - new report, titled Biliary Stents Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Biliary Stents market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Biliary Stents market. The report offers an overview of the market, which
High Prevalence of Biliary Diseases Across the Globe is Driving the Biliary Sten …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.
Rise in Surgical Procedures of Biliary Diseases is Expected to Boost the Biliary …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.